Caripa200 ml

Caripa is a herbal (nutraceutical) supplement derived from the leaves of the papaya plant (Carica papaya). It is used in Bangladesh and other countries mainly as an adjunctive supportive measure in the following settings:

Adjunct use with preliminary evidence

• Dengue fever-associated thrombocytopenia: Caripa is most commonly used as an add-on supportive measure to help support platelet counts in patients with dengue fever who have a low platelet count (thrombocytopenia). Several small-to-moderate randomized controlled trials and a pilot study have reported a trend toward faster platelet count recovery with Caripa compared to placebo, but evidence remains limited in scale and consistency, and it is not a substitute for standard hospital-based monitoring and management of dengue fever.
• Chemotherapy-induced thrombocytopenia: Caripa has also been studied as an adjunct to help support platelet recovery in patients with low platelet counts caused by cancer chemotherapy, used alongside standard oncology care, not in place of it.

Traditional/complementary uses (limited robust clinical evidence)

• General digestive support and traditional use for bloating or indigestion.
• Traditional use for general immune support and as an antioxidant/anti-inflammatory supplement.

These traditional uses are based largely on historical/ethnobotanical use and preliminary laboratory or small human studies rather than large, robust randomized controlled trials, and Caripa should not be relied upon as a primary treatment for any of these conditions.

Carica Papaya Leaf Extract is available in Bangladesh in the following common dosage forms:

• Capsule: 250 mg of standardized Carica Papaya Leaf Extract per capsule.
• Oral syrup/liquid: 275 mg/5 mL of Carica Papaya Leaf Extract.

Exact standardization (e.g., percentage of active constituents such as papain, chymopapain, and flavonoids) can vary between manufacturers, as this is a botanical extract rather than a single isolated chemical entity.

Caripa is a botanical extract obtained from the leaves of the papaya tree, used as a dietary/herbal supplement rather than as a conventional pharmaceutical drug. It is popularly known in South and Southeast Asia for its traditional and complementary use in supporting platelet counts during dengue fever, in addition to standard medical treatment.

Caripa contains a mixture of naturally occurring compounds, including flavonoids (such as quercetin and kaempferol), alkaloids (such as carpaine), enzymes (such as papain and chymopapain), vitamin C, and other phytochemicals believed to contribute to its reported antioxidant and immunomodulatory effects.

While preliminary clinical studies on Caripa are encouraging for its use as a supportive adjunct in dengue-associated thrombocytopenia, the overall body of high-quality, large-scale randomized controlled trial evidence remains limited, and it should never be used in place of appropriate medical evaluation and treatment for dengue fever or other serious illnesses.

Caripa belongs to the class of herbal/nutraceutical supplements (phytotherapeutic agents). It is not classified as a conventional prescription pharmaceutical and is generally sold as an over-the-counter herbal preparation in Bangladesh.

The precise mechanism by which Carica Papaya Leaf Extract may influence platelet counts is not fully established, but several proposed mechanisms have been suggested based on laboratory and preliminary clinical research:

• Bone marrow stimulation: Some evidence suggests Carica Papaya Leaf Extract may promote proliferation of hematopoietic stem/progenitor cells and megakaryocytes, potentially supporting platelet production.
• Antioxidant activity: Flavonoids present in Carica Papaya Leaf Extract may reduce oxidative stress on platelets and endothelial cells during acute febrile illness.
• Anti-inflammatory effects: Carica Papaya Leaf Extract has demonstrated modulation of certain inflammatory cytokines in preliminary studies, which may theoretically support recovery during viral febrile illness.

These mechanisms are based largely on in-vitro and animal studies together with a limited number of human clinical trials, and are not as firmly established as the mechanisms of conventional pharmaceutical agents.

Caripa capsules and syrup are taken by mouth (orally).

• May be taken with or without food; taking with food may reduce the mild stomach upset some users report.
• Syrup formulations should be measured using the calibrated measuring cup/spoon provided with the product, not an ordinary household spoon, to ensure dosing accuracy, especially in children.
• Shake the syrup bottle well before each use.
• Swallow capsules whole with a glass of water; do not chew or crush unless instructed otherwise by a physician.
• Caripa should be used alongside, and never as a replacement for, standard physician-directed monitoring and treatment (such as fluid management and platelet monitoring) during dengue fever.

Formal, well-controlled drug-interaction studies with Caripa are limited. Based on its proposed pharmacological effects and clinical experience, the following interactions are considered clinically relevant:

• Antiplatelet and anticoagulant drugs (e.g., aspirin, clopidogrel, warfarin, heparin, direct oral anticoagulants): Caripa has been reported to affect platelet counts and function; theoretically, concurrent use could alter bleeding risk. Use with caution and under medical supervision, with closer monitoring where clinically indicated.
• Antidiabetic medications: Papaya leaf preparations have been reported in some studies to have a mild blood-glucose-lowering effect; concurrent use with insulin or oral hypoglycemic agents may theoretically increase the risk of hypoglycemia, so blood glucose should be monitored.
• Antihypertensive medications: There are limited reports suggesting a possible mild blood-pressure-lowering effect; caution is advised with concurrent antihypertensive therapy.

Patients should inform their physician of all prescription medicines, over-the-counter drugs, and other herbal supplements they are taking before starting Caripa.

Caripa is generally well tolerated at recommended doses, and serious adverse effects are uncommon. Reported side effects include:

• Mild gastrointestinal upset (nausea, stomach discomfort, or diarrhea)
• Mild allergic skin reactions (rash, itching) in sensitive individuals
• Rarely, more significant hypersensitivity reactions in patients with latex or papaya allergy (see Contraindications)

Patients should seek medical attention promptly if they develop signs of a significant allergic reaction (e.g., swelling of the face/throat, difficulty breathing, widespread rash) while taking Caripa.

Caripa is not recommended for use during pregnancy. Papaya leaf and unripe papaya preparations have traditional associations with uterine-stimulant and abortifacient effects, and safety during pregnancy has not been established in controlled human studies. Caripa should be avoided in pregnant women unless specifically directed and supervised by a physician who judges the potential benefit to outweigh the potential risk.

Data on the safety of Caripa during breastfeeding are also lacking. As a precaution, breastfeeding women should avoid Caripa unless advised otherwise by a physician, and should consult their doctor before use.

Caripa should never be used as a substitute for appropriate medical evaluation and treatment of dengue fever or other serious febrile illness. Dengue fever can progress rapidly and cause serious complications (such as dengue hemorrhagic fever or dengue shock syndrome); patients with suspected dengue must seek prompt medical evaluation, and Caripa should only be used as an adjunct alongside standard medical care, hydration, and clinical monitoring, never as a replacement for it.

• Use with caution in patients with a known latex or papaya allergy (see Contraindications).
• Use with caution in patients on antiplatelet/anticoagulant therapy, antidiabetic medication, or antihypertensive medication (see Interactions).
• Avoid in pregnancy; use with caution during breastfeeding (see Pregnancy and Lactation).
• Because Caripa is a botanical/herbal product, standardization and quality can vary between manufacturers; use only products obtained from a reliable, licensed pharmacy source.
• Do not delay seeking emergency care for warning signs of severe dengue (persistent vomiting, severe abdominal pain, bleeding, difficulty breathing, lethargy) while relying on Caripa.

There is limited formal data on overdose with Caripa, as it is a herbal supplement typically used at modest doses. Taking substantially more than the recommended dose may increase the likelihood of gastrointestinal upset (nausea, vomiting, diarrhea) or allergic reactions in susceptible individuals.

If an overdose of Caripa is suspected, or if any concerning symptoms develop, seek immediate medical attention or contact a poison control center/emergency services. Do not attempt to manage a suspected overdose at home without professional medical guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Keep the container tightly closed. Discard any unused syrup after the period indicated on the label once opened.

Renal or hepatic impairment: There is no well-established dosage adjustment for Caripa in patients with kidney or liver impairment, as formal pharmacokinetic studies in these populations are lacking. Such patients should use Caripa only under medical supervision.

Elderly: No specific dose adjustment is established for elderly patients, but this population may be more likely to be on antiplatelet, anticoagulant, or antidiabetic medications, so the interaction cautions above should be considered (see Interactions).

Children: See Pediatric Uses for age-specific dosing information.

Pregnancy and breastfeeding: See Pregnancy and Lactation.

Caripa is generally used short-term as a supportive adjunct during the acute phase of dengue fever, typically for about 5 days (syrup) or up to approximately 5 to 12 days (capsule), or until platelet counts recover, as directed and monitored by the treating physician. It is not intended for indefinite or long-term continuous use, and there is limited evidence to support prolonged use beyond the acute illness period.

Carica Papaya Leaf Extract falls under the drug/product class of herbal supplements / phytotherapeutic (plant-derived) preparations, specifically within the sub-category of botanical extracts used for hematologic (platelet) support.

Carica Papaya Leaf Extract is thought to act through a combination of proposed mechanisms, including stimulation of megakaryocyte/platelet production in the bone marrow, antioxidant effects that may protect platelets and endothelial cells during viral illness, and mild anti-inflammatory activity. See Pharmacology for full details, as the precise mode of action has not been definitively established through large mechanistic studies in humans.

Caripa syrup is used in children as an adjunct for dengue-associated thrombocytopenia under medical supervision, with age-based dosing as follows:

• Children 1-5 years: 1 teaspoonful (5 mL) of syrup, 3 times daily, generally for around 5 days.
• Children 5-18 years: 2 teaspoonfuls (10 mL) of syrup, 3 times daily, generally for around 5 days.

Formal safety and efficacy data in children are more limited than in adults, and Caripa should be used in pediatric patients only under the guidance of a physician, as an adjunct to standard hospital-based dengue management, never as a substitute for it. Use in infants under 1 year of age is not established and should be avoided unless specifically directed by a pediatrician.